No Data
No Data
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12
H.C. Wainwright analyst Douglas Tsao maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 37.
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Buy Rating Affirmed for Coherus Biosciences on CHS-114's Promising Clinical Data and Strong Financial Projections
Express News | Coherus BioSciences: Chs-114 Shown to Have Acceptable Safety Profile With No Dose-Limiting Toxicities in Heavily Pretreated Patients With Solid Tumors
Express News | Coherus Presents Preliminary Results From Phase I Dose Escalation Study of Its Anti-Chemokine Receptor 8 (Ccr8) Antibody, Chs-114, at the 2024 American Society of Clinical Oncology (Asco) Annual Meeting
Coherus Presents Preliminary Results From Phase I Dose Escalation Study of Its Anti-chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago.
No Data
买跌不追涨 : 这个消息感觉一般
TrytosaveabitOP 买跌不追涨: As far as compared to other BIO news! You are correct